VentiRx Pharmaceuticals

VentiRx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of medicines for the treatment of cancer, and respiratory and autoimmune diseases. The company focuses on the development of small molecule product candidates targeting toll-like receptor 8 (TLR8) agonists and antagonists. Its product pipeline comprises VTX-2337, a small molecule TLR8 agonist that stimulates myeloid dendritic cells and monocytes, and enhances natural killer cell responses for the treatment of solid tumors, ovarian and breast cancers, and NHL and SCHN; VTX-1463, a stand alone agent for the treatment of seasonal and perennial allergies; TLR8 antagonists for the treatment of autoimmune diseases; and multiple compounds that are treated as vaccine adjuvants. The company has a strategic agreement/collaboration with Celgene Corporation. VentiRx Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Seattle, Washington with operations in San Diego.

VentiRx Pharmaceuticals headquartered in United States, North America, operates in the Biotechnology, Health Care, Therapeutics sector. The company focuses on Biotechnology and has secured $5.0B in funding across 48 round(s). With a team of 11-50 employees, VentiRx Pharmaceuticals is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - VentiRx Pharmaceuticals, raised $25.0M. Discover more about their projects, partnerships, and impact on our platform.